trial summary · NCT07614022
A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)
A Phase I Study of the Bcl-2/Bcl-XL Inhibitor LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, Philadelphia-Chromosome/BCR::ABL1-Positive Acute Lymphoblastic Leukemia
Trial record from the TrialBase DB dataset, status RECRUITING, condition Philadelphia Positive Acute Lymphoblastic Leukemia, sponsored by Wake Forest University Health Sciences. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
The purpose of this research study is to see if a drug called LP-118 is safe and effective for treating adults with Philadelphia chromosome-positive (Ph+) B cell acute lymphoblastic leukemia (ALL), when given with ponatinib, dexamethasone, methotrexate and blinatumomab (the standard treatment for this type of cancer).
Source record: https://clinicaltrials.gov/study/NCT07614022
Facts
| registry id | NCT07614022 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1 |
| study type | INTERVENTIONAL |
| lead condition | Philadelphia Positive Acute Lymphoblastic Leukemia |
| sponsor | Wake Forest University Health Sciences |
| sponsor class | OTHER |
| enrollment | 26 |
| start date | 2026-12 |
| primary completion | 2030-03 |
| completion | 2030-03 |
| results posted | not reported |
Conditions
- Philadelphia Positive Acute Lymphoblastic Leukemia
Interventions
- LP-118
Countries
- United States
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.